8-KShareholder MattersExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Rights Modification (Dec 13, 2006)

Filed December 13, 2006For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K report on December 13, 2006, to announce a material modification to the rights of its security holders. The core of this filing is the approval and execution of Amendment Number 3 to the company's Rights Agreement, originally established in 1999. This amendment specifically alters the expiration date of Abbott's preferred stock purchase rights (the 'Rights'). For investors, the most critical takeaway is that these Rights, which typically serve as a defensive measure against hostile takeovers, have now expired. The amendment moved the expiration date from November 10, 2009, to the close of business on December 11, 2006. This means that as of December 11, 2006, all outstanding preferred stock purchase rights under this agreement are no longer in effect.

Key Highlights

  • 1Abbott Laboratories amended its existing Rights Agreement.
  • 2The amendment, dated December 8, 2006, changes the expiration date of the company's preferred stock purchase rights.
  • 3The preferred stock purchase rights originally set to expire on November 10, 2009, have now expired.
  • 4All outstanding Rights under the Rights Agreement expired as of the close of business on December 11, 2006.
  • 5This action effectively removes a common anti-takeover provision from Abbott's corporate structure.
  • 6The filing was made on December 13, 2006, with the earliest event date reported as December 8, 2006.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report a material modification to the rights of Abbott Laboratories' security holders, specifically the expiration of its preferred stock purchase rights under its Rights Agreement.

Preferred stock purchase rights, often referred to as 'poison pills,' are a corporate governance mechanism. They are typically issued to existing shareholders to make a hostile takeover of the company prohibitively expensive, thereby protecting the company and its management from unsolicited acquisition attempts.

The expiration of these Rights means that a key anti-takeover defense for Abbott Laboratories is no longer in place. While this doesn't automatically signal an acquisition attempt, it removes a significant hurdle for any potential acquirer interested in gaining control of the company.

No, the expiration of the Rights Agreement does not automatically mean Abbott Laboratories is being acquired or will be acquired. It simply means that a specific defensive measure against hostile takeovers has expired, making the company potentially more vulnerable to such attempts if they were to occur.